Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesper Jensen

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
JAMA Cardiology|January 6, 2021
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical TrialMassar Omar, Jesper Jensen, Mulham Ali, et al.
JACC. Advances|October 24, 2025
Albuminuria in Type 2 Diabetes and Risk of Cardiorenal OutcomesSaaima Parveen, Morten Malmborg, Anojhaan Arulmurugananthavadivel, et al.
Journal of Clinical Lipidology|January 22, 2025
Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLEFrida Emanuelsson, Jesper Jensen, Massar Omar, et al.
Journal of the American College of Cardiology|December 4, 2020
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection FractionMassar Omar, Jesper Jensen, Peter H Frederiksen, et al.
Optics Express|June 2, 2009
Ultra-large bandwidth hollow-core guiding in all-silica Bragg fibers with nano-supportsGuillaume Vienne, Yong Xu, Christian Jakobsen, et al.
Trials|June 23, 2019
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)Jesper Jensen, Massar Omar, Caroline Kistorp, et al.
Medrxiv : the Preprint Server for Health Sciences|June 12, 2025
Effects of Empagliflozin on Right Ventricular Function in Heart Failure with Reduced Ejection FractionMassar Omar, Jesper Jensen, Peter H Frederiksen, et al.
ESC Heart Failure|February 19, 2026
Effects of Empagliflozin on Right Ventricular Free-Wall Strain in Patients with Heart Failure and Reduced Ejection FractionMassar Omar, Jesper Jensen, Mulham Ali, et al.
The Lancet. Healthy Longevity|September 21, 2023
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide studyMariam Elmegaard Malik, Jawad Haider Butt, Jarl Emanuel Strange, et al.
Journal of the American Heart Association|April 9, 2026
Care and Outcomes of New-Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022Sofie-Louise Feentved Ødum, Clara Friis, Caroline Hartwell Garred, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
JAMA Cardiology|January 6, 2021
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical TrialMassar Omar, Jesper Jensen, Mulham Ali, et al.
JACC. Advances|October 24, 2025
Albuminuria in Type 2 Diabetes and Risk of Cardiorenal OutcomesSaaima Parveen, Morten Malmborg, Anojhaan Arulmurugananthavadivel, et al.
Journal of Clinical Lipidology|January 22, 2025
Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLEFrida Emanuelsson, Jesper Jensen, Massar Omar, et al.
Journal of the American College of Cardiology|December 4, 2020
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection FractionMassar Omar, Jesper Jensen, Peter H Frederiksen, et al.
Optics Express|June 2, 2009
Ultra-large bandwidth hollow-core guiding in all-silica Bragg fibers with nano-supportsGuillaume Vienne, Yong Xu, Christian Jakobsen, et al.
Trials|June 23, 2019
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)Jesper Jensen, Massar Omar, Caroline Kistorp, et al.
Medrxiv : the Preprint Server for Health Sciences|June 12, 2025
Effects of Empagliflozin on Right Ventricular Function in Heart Failure with Reduced Ejection FractionMassar Omar, Jesper Jensen, Peter H Frederiksen, et al.
ESC Heart Failure|February 19, 2026
Effects of Empagliflozin on Right Ventricular Free-Wall Strain in Patients with Heart Failure and Reduced Ejection FractionMassar Omar, Jesper Jensen, Mulham Ali, et al.
The Lancet. Healthy Longevity|September 21, 2023
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide studyMariam Elmegaard Malik, Jawad Haider Butt, Jarl Emanuel Strange, et al.
Journal of the American Heart Association|April 9, 2026
Care and Outcomes of New-Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022Sofie-Louise Feentved Ødum, Clara Friis, Caroline Hartwell Garred, et al.
Pageof 8